Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Schuchter on the Next Steps in Melanoma Research

July 7th 2011

Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research

Dr. Kris Talks About Defining Biomarkers

July 5th 2011

Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers

Dr. Hoos Discusses the Clinical Kinetics of Immunotherapy

July 1st 2011

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy

Routine Tests and Procedures in Cardiac Patients May Increase Cancer Risk

June 30th 2011

Researchers have reported that acute myocardial infarction (MI) patients who are exposed to low-dose ionizing radiation from imaging and therapeutic procedures may be at increased risk of cancer.

Donna Berry, PhD, RN 2011 ONS Distinguished Researcher Award Winner

June 29th 2011

Nurse scientist Donna Berry, PhD, RN, received the 2011 ONS Distinguished Researcher Award, which recognizes a nurse researcher whose work has enhanced the science and practice of oncology nursing.

Population Stratification and Cancer Risk Assessment: An Interview With Jill Barnholtz-Sloan, PhD

June 28th 2011

Population stratification refers to differences in allele frequencies between cases and controls, resulting from systematic differences in ancestry, as opposed to associations between genes and disease.

4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets

June 27th 2011

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

June 24th 2011

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

HER2 Signaling Beckons: Dimerization Process, Combination Therapies Highlight New Research

June 24th 2011

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Infante on the Next Step in Melanoma Research

June 23rd 2011

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Kris Discusses the Pemetrexed Trial Results

June 23rd 2011

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Vismodegib Trial Yields Benefits in BCC patients

June 20th 2011

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Hedgehog Pathway Inhibitor GDC-0449 Reduces Lesion Size in Patients With Basal Cell Carcinoma

June 20th 2011

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

Smart Moves? E-patient Systems Rise Amid Skepticism

June 16th 2011

During the past 20 years, disease management systems have mushroomed in medicine

Emerging Cancer Vaccines Appear to Be on Track for Major Advances

June 15th 2011

Both industry and clinical sources agree that cancer vaccine research is finally on the right track to achieve major advances in treatment.

Scientists Pioneer Technology to Detect More Chromosomal Aberrations in Cancer Tumors

June 14th 2011

The investigators developed a computer tool that is dramatically better for finding genetic missteps that promote cancer.

Dr. Paz-Ares Discusses Pemetrexed Clinical Trial

June 13th 2011

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

University of Wisconsin Carbone Cancer Center: A Tradition of Comprehensive, Multidisciplinary Care

June 13th 2011

Currently, more than 250 physicians and scientists work in concert to provide state-of- the art diagnosis, treatment, and aftercare for the more than 20,000 patients seen each year at the UW hospitals, clinics, and affiliate clinical facilities

Dr. Chapman Describes the Vemurafenib Clinical Trial

June 10th 2011

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Dr. Vogelzang Discusses Cabozantinib Trial Design

June 9th 2011

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib Trial Design